|
|
Volumn 355, Issue 9207, 2000, Pages 863-864
|
|
Implications of discontinuation of doxazosin arm of ALLHAT
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADRENERGIC RECEPTOR BLOCKING AGENT;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
ANGIOTENSIN RECEPTOR ANTAGONIST;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
CALCIUM ANTAGONIST;
CHLORTALIDONE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
DOXAZOSIN;
BLOOD PRESSURE REGULATION;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG EFFICACY;
DRUG LEGISLATION;
DRUG SAFETY;
DYSLIPOPROTEINEMIA;
HEALTH CARE FINANCING;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
INSULIN RESISTANCE;
ISCHEMIC HEART DISEASE;
NOCTURIA;
NOTE;
PRIORITY JOURNAL;
PROSTATE HYPERTROPHY;
|
|
EID: 0034635831
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(00)00092-1 Document Type: Note |
|
Times cited : (64)
|
|
References (12)
|
